VIEWPOINTS Archives

VIEWPOINTS

Inside neffy’s Launch Strategy: A Stimulating Conversation with Richard Lowenthal, CEO & Co-Founder of ARS Pharmaceuticals

Shots: Inconsistent access to epinephrine auto-injectors continues to be a major unmet need in the management of anaphylaxis neffy, an innovative intranasal epinephrine spray, provides a needle-free alternative for the emergency treatment of severe allergic reactions, including anaphylaxis, in adults and children aged four years and older who weigh at least 33 lbs Richard Lowenthal,…

November 3, 2025

Optimizing Life Sciences CRM: A Candid Conversation with Akshay Kapadia from Conexus Solutions

Shots: As life sciences organizations increasingly adopt integrated data, AI, and advanced analytics, CRM platforms are becoming powerful tools to anticipate customer needs, personalize engagements, and measure impact in real-time across multiple channels In the coming years, CRM will transform into a strategic intelligence hub, empowering teams to make data-driven decisions and helping companies…

October 27, 2025

Enhancing R&D Prowess in Oncology: Denis R. Beckford-Vera from Champions Oncology in Conversation with PharmaShots

Shots: The complexity of human physiology continues to challenge drug development, as conventional models often fail to provide critical insights, resulting in high attrition rates Champions Oncology bridges this gap through patient-derived xenograft and ex vivo platforms built from real tumors, integrated with radiolabeled compounds for deeper R&D insights Denis R. Beckford-Vera, Head of Radiopharmacology…

October 13, 2025

Breaking New Ground in Oncology: Leonard Mazur from Citius Pharmaceuticals in Conversation with PharmaShots

Shots: Citius Pharmaceuticals celebrates its first-ever FDA approval with Lymphir, a novel therapy for relapsed or refractory cutaneous T-cell lymphoma In an exclusive conversation, Leonard Mazur, Co-Founder and CEO at Citius Pharmaceuticals, shares insights on Lymphir’s launch strategy and its potential impact on the oncology landscape Leonard also highlights Mino-Lok, Citius’ innovative…

October 6, 2025

Expanding Solid Tumor Care: Shaun Bagai from RenovoRx in a Stimulating Conversation with PharmaShots

Shots: RenovoRx, a clinical-stage life sciences company, is developing targeted oncology therapies and has created RenovoCath, an FDA-cleared novel drug delivery device. Its proprietary TAMP therapy platform enables precise delivery of therapeutics across the arterial wall near the tumor site, directly targeting the tumor while potentially reducing the toxicities linked to systemic IV chemotherapy. In…

September 29, 2025

Navigating Amorphous Calcium Carbonate Therapies: Eden Ben from Amorphical in Conversation with PharmaShots

Shots: ACC therapies introduce a novel treatment approach by modulating local pH, promoting bone remodeling, and reducing inflammation, with potential applications in osteoarthritis, calcium deficiencies, late-stage cancers, and bone disorders. Amorphical’s AMOR-18 showed encouraging results in an interim Phase II clinical trial involving COVID-19 patients. PharmaShots speaks with Eden Ben, CEO of Amorphical, to discuss…

September 22, 2025

Pain Management & Beyond: Paul Howe from Protega Pharmaceuticals in a Stimulating Conversation with PharmaShots

Shots: Abuse-deterrent products are prescription medications, primarily opioids and certain stimulants, designed to resist common methods of misuse, such as crushing, snorting, or injecting Protega Pharmaceuticals’ RoxyBond is the first and only FDA-approved, immediate-release abuse-deterrent opioid indicated for managing severe pain when alternative treatments are inadequate PharmaShots is pleased to feature Paul Howe, Chief Operations…

September 17, 2025

Wearable Drug Delivery System: Mehul Desai from Enable Injections in a Riveting Conversation with PharmaShots

Shots: Enable Injections recently shared survey findings indicating that many oncology assets with strong commercial potential are often prematurely abandoned or deprioritized due to challenges in formulating small volumes (<3 mL) for subcutaneous delivery. To address this need, Enable Injections developed enFuse, an innovative, hands-free, wearable drug delivery platform with a discreet, hidden needle that…

September 15, 2025

Unlocking Approval: Joshua Salsi from Biocon Biologics in a Riveting Conversation with PharmaShots

Shots: The United States has about 38.4 million people living with diabetes, representing 11.6% of the total population. With growing prevalence, there is a significant unmet need for affordable diabetes medications. Biocon Biologics recently announced the FDA approval of Kirsty, the first and only interchangeable biosimilar to NovoLog (Insulin Aspart). Joshua Salsi, the Head of…

September 8, 2025

AI-Mediated Recalls: Shawn Opatka from Honeywell in a Riveting Dialogue Exchange with PharmaShots

Shots: Product recalls in biopharma and MedTech incur an unanticipated drain on budget, costing the industry between $2.5B to $5B per year on average Honeywell’s TrackWise Recall Management helps biopharma and MedTech companies plan and execute recall processes seamlessly, contributing to improved patient safety and faster response times Shawn Opatka, Vice President & General Manager,…

September 1, 2025